Recent advancements in colorectal cancer detection include a new AI test and a groundbreaking blood test approved by the FDA. The AI test developed by the University of Leeds can predict the recurrence of bowel cancer by assessing immune cells in tumors, potentially helping patients avoid unnecessary chemotherapy. Meanwhile, the FDA approved the Shield blood test from Guardant, aimed at adults aged 45 and older, which detects colon cancer through DNA fragments shed by tumor cells. Although the Shield test is not a replacement for colonoscopies, it offers a non-invasive alternative that could increase screening rates, particularly among those who avoid traditional methods. Medical professionals express optimism that these innovations will lead to earlier detection and improved treatment outcomes for colorectal cancer patients. The introduction of the Shield test is expected to enhance accessibility and potentially save more lives, especially in underserved communities.